Teladoc initiated with an Overweight at Stephens. Stephens analyst Jacob Johnson initiated Teladoc with an Overweight rating and a price target of $75, saying the company is an “industry leader” in the telehealth industry which is undergoing “considerable growth” that is still in its “early innings”. The analyst also notes that any M&A by Teladoc should “increase the value of its platform by adding capabilities and geographies”, adding that while its gross margins may decline as a result of a “shifting revenue mix,” the company’s operating leverage should result in expanding EBITDA margins. Johnson further states that Teladoc shares are not cheap, but still trade “at a discount to high-growth healthcare and tech peers.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.